References
- O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi:https://doi.org/10.1056/NEJMoa022457.
- Druker BJ. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417. doi:https://doi.org/10.1056/NEJMoa062867.
- Pocaly M, Lagarde V, Etienne G, et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia. 2006;21:93–101. doi:https://doi.org/10.1038/sj.leu.2404463.
- Warsch W, Kollmann K, Eckelhart E, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117:3409–3420. doi:https://doi.org/10.1182/blood-2009-10-248211.
- Ha SA, Kim S, Shin SM, et al. Gene expression signatures associated with the resistance to imatinib. Leukemia. 2006;20:1542–1550. doi:https://doi.org/10.1038/sj.leu.2404310.
- Falzone L, Lupo G, La Rosa GRM, et al. Identification of novel MicroRNAs and their diagnostic and prognostic significance in oral cancer. Cancers. 2019;11:610. doi:https://doi.org/10.3390/cancers11050610.
- Bao F, Polk P, Nordberg ML, et al. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007;31:1511–1520. doi:https://doi.org/10.1016/j.leukres.2007.03.002.
- Miyauchi M, Koya J, Arai S, et al. ADAM8 is an antigen of tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells identified by patient-derived induced pluripotent stem cells. Stem Cell Rep. 2018;10:1115–1130. doi:https://doi.org/10.1016/j.stemcr.2018.01.015.
- Avilés-Vázquez S, Chávez-González A, Hidalgo-Miranda A, et al. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. Cancer Med. 2017;6:2942–2956. doi:https://doi.org/10.1002/cam4.1187.
- Xu Y, Shen K. Identification of potential key genes associated with ovarian clear cell carcinoma. Cancer Manage Res. 2018;10:5461–5470. doi:https://doi.org/10.2147/CMAR.S187156.
- Li L, Lei Q, Zhang S, et al. Screening and identification of key biomarkers in hepatocellular carcinoma: evidence from bioinformatic analysis. Oncol Rep 2017;38:2607–2618. doi:https://doi.org/10.3892/or.2017.5946.
- Zhong M, Wu Y, Ou W, et al. Identification of key genes involved in type 2 diabetic islet dysfunction: a bioinformatics study. Biosci Rep. 2019;39:5. doi:https://doi.org/10.1042/BSR20182172.
- Huang DW, Sherman BT, Tan Q, et al. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8:R183. doi:https://doi.org/10.1186/gb-2007-8-9-r183.
- Li GM, Zhang CL, Rui RP, et al. Bioinformatics analysis of common differential genes of coronary artery disease and ischemic cardiomyopathy. Eur Sci Med Farmacol. 2018;22:3553–3569. doi:https://doi.org/10.26355/eurrev_201806_15182.
- Klukas C, Schreiber F. Dynamic exploration and editing of KEGG pathway diagrams. Bioinformatics. 2007;23:344–350. doi:https://doi.org/10.1093/bioinformatics/btl611.
- Eden E, Navon R, Steinfeld I, et al. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinf. 2009;10:48. doi:https://doi.org/10.1186/1471-2105-10-48.
- Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41:D808–D815. doi:https://doi.org/10.1093/nar/gks1094.
- Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504. doi:https://doi.org/10.1101/gr.1239303.
- Bandettini WP, Kellman P, Mancini C, et al. Multicontrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn R. 2012;14:83. doi:https://doi.org/10.1186/1532-429X-14-83.
- Maere S, Heymans K, Kuiper M. BiNGO: a cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21:3448–3449. doi:https://doi.org/10.1002/pssc.200778445.
- Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Mol Biol 2011;696:291–303. doi:https://doi.org/10.1007/978-1-60761-987-1_18.
- Gao J, Aksoy BA, Dogrusoz U. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signaling. 2013;6:11. doi:https://doi.org/10.1126/scisignal.2004088.
- Bozkurt S, Ozkan T, Ozmen F, et al. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells. Hematology. 2013;18:217–223. doi:https://doi.org/10.1179/1607845412Y.0000000056.
- Juan L, Yujing Z, Aichun L, et al. Distinct dasatinib-induced mechanisms of apoptotic response and exosome release in imatinib-resistant human chronic myeloid leukemia cells. Int J Mol Sci. 2016;17:531. doi:https://doi.org/10.3390/ijms17040531.
- Guo-Bao W, Xiao-Qin C, Qi-Rong G, et al. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of β1-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma. 2010;51:1090–1097. doi:https://doi.org/10.3109/10428191003746315.
- Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54. doi:https://doi.org/10.1038/nrc968.
- Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921. doi:https://doi.org/10.1038/nm0897-917.
- Glodkowska-Mrowka E, Solarska I, Mrowka P, et al. Differential expression of BIRC family genes in chronic myeloid leukaemia BIRC3 and BIRC8 as potential new candidates to identify disease progression. Brit J Haematol. 2014;164:740–742. doi:https://doi.org/10.1111/bjh.12663.
- Carter BZ. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006;107:1555–1563. doi:https://doi.org/10.1182/blood-2004-12-4704.
- Stella S, Tirro E, Conte E, et al. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol Cancer Ther. 2013;12:1085–1098. doi:https://doi.org/10.1158/1535-7163.MCT-12-0550.
- Soleimanpour E, Babaei E. Survivin as a potential target for cancer therapy. Asian Pac J Cancer P. 2015;16:6187–6191. doi:https://doi.org/10.7314/APJCP.2015.16.15.6187.
- Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:50–71. Available from: https://cancerres.aacrjournals.org/content/58/22/5071.
- Adebayo BO, Kuang-Tai K, Li-Ping Y, et al. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Exp Cell Res. 2018;370:519–530. doi:https://doi.org/10.1016/j.yexcr.2018.07.017.
- Lv YG, Yu F, Yao Q, et al. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2:100. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256445/?report=abstract.
- Waligrska-Stachura J, Sawicka-Gutaj N, Zabel M, et al. Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level. Oncol Lett. 2017;13:24–37. doi:https://doi.org/10.3892/ol.2017.5713.
- Mohamed S, Yasufuku K, Nakajima T, et al. Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications. Eur Respir J. 2009;33:127–133. doi:https://doi.org/10.1183/09031936.00068708.
- Gudas JM, Payton M, Thukral S, et al. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol. 1999;19:612–622. doi:https://doi.org/10.1128/MCB.19.1.612.
- Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69:6565–6572. doi:https://doi.org/10.1158/0008-5472.CAN-09-0913.
- Payton M, Scully S, Chung G, et al. Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene. 2002;21:8529–8534. doi:https://doi.org/10.1046/j.1365-2958.2000.01764.x.
- Müller-Tidow C, Metzger R, Kügler K, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 2001;61:647–653. doi:https://doi.org/10.1016/S0165-4608(00)00343-5.
- He H, Kondo Y, Ishiyama K, et al. Two unique HLA-A* 0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia. 2020: 1–11. doi:https://doi.org/10.1038/s41375-019-0698-z.
- Kim WS, Lee MJ, Kim DH, et al. 5′-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Leuk Res. 2013;37:427–433. doi:https://doi.org/10.1016/j.leukres.2012.12.017.
- Ishimi Y. A DNA helicase activity is associated with an MCM4, -6, and -7 protein complex. J Biol Chem. 1997;272:24508–24513. doi:https://doi.org/10.1074/jbc.272.39.24508.
- Ishimi Y, Komamura-Kohno Y, Kwon HJ, et al. Identification of MCM4 as a target of the DNA replication block checkpoint system. J Biol Chem. 2003;278:24644–24650. doi:https://doi.org/10.1074/jbc.M213252200.
- Kikuchi J, Kinoshita I, Shimizu Y, et al. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer. 2011;72:229–237. doi:https://doi.org/10.1016/j.lungcan.2010.08.020.
- Kwok HF, Zhang SD, McCrudden CM, et al. Prognostic significance of minichromosome maintenance proteins in breast cancer. Am J Cancer Res. 2015;5:52. Available from: https://pubmed.ncbi.nlm.nih.gov/25628920/.
- Tilghman J, Wu H, Sang Y, et al. HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells. Cancer Res. 2014;74:3168–3179. doi:https://doi.org/10.1158/0008-5472.CAN-13-2103.
- Fu X, Zhu Y, Zheng B, et al. KIFC1, a novel potential prognostic factor and therapeutic target in hepatocellular carcinoma. Int J Oncol. 2018;52:1912–1922. doi:https://doi.org/10.3892/ijo.2018.4348.
- Sekino Y, Oue N, Shigematsu Y, et al. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer. Urol Oncol. 2017;35:1–8. doi:https://doi.org/10.1016/j.urolonc.2016.08.007.
- Wang P, Zou F, Zhang X. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009;69:8157–8165. doi:https://doi.org/10.1158/0008-5472.CAN-09-1996.
- Cangi MG, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–761. doi:https://doi.org/10.1172/JCI9174.
- Wu W, Fan YH, Kemp BL, et al. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082–4085. Available from: https://cancerres.aacrjournals.org/content/58/18/4082.
- Hanning Y, Zhiyao X, Mingming C, et al. Overexpression of zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. OncoTargets Ther. 2018;11:689–702. doi:https://doi.org/10.2147/OTT.S152138.
- Li T, Xue H, Guo Y, et al. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer. Oncol Rep. 2014;31:1825–1831. doi:https://doi.org/10.3892/or.2014.3045.
- Jung CR, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2016;43:1042–1052. doi:https://doi.org/10.1002/hep.21137.
- Li H, Yin C, Zhang B, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013;34:2145–2155. doi:https://doi.org/10.1093/carcin/bgt158.
- Demeure MJ, Coan KE, Grant CS, et al. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery. 2013;154:1405–1416. doi:https://doi.org/10.1016/j.surg.2013.06.058.